Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06567717 · ClinicalTrials.gov registry record · Phase 2

Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis

A Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by Cedars-Sinai Medical Center.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
1
Study location

NCT06567717 is a Phase 2 study of Idiopathic Pulmonary Fibrosis that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 60 participants, below the 750-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06567717, a Phase 2 study of Idiopathic Pulmonary Fibrosis, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn if a clinical trial for idiopathic pulmonary fibrosis (IPF) can recruit and retain participants from their home to study whether a combination of zinc and nicotinamide riboside can treat iIPF. The main questions are: Can the investigators recruit participants, and can participants complete study procedures without physically coming into specific clinical trial sites? Can people with IPF experience improvement in symptoms, quality of life, or functioning if they are take these supplements? The investigators will compare zinc and nicotinamide riboside to matched placebos (look-alike substances that contain no drug) to see if these supplements treat symptoms or lung function in people with IPF. Participants will: Take drug these supplements twice a day for 24 weeks. Complete pulmonary function testing and six minute walk tests with their own pulmonologists every 12 weeks. Complete a high resolution CT scan at the start and end of the study. Complete video study visits with the research team every 4 weeks. Complete surveys about their symptoms and the number of times they take the medication.

Conditions Studied

Idiopathic Pulmonary Fibrosis

Interventions

  • DRUG Zinc
  • OTHER Placebos for zinc and nicotinamide riboside
  • DRUG Nicotinamide riboside

Study Locations (1)

California

  • Cedars-Sinai - Los Angeles

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-11-03
Est. Completion 2027-01
Phase Phase 2

Sponsor

Cedars-Sinai Medical Center

339 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06567717

The ClinicalTrials.gov registry entry for NCT06567717 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 750-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (92% lower). The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 3 interventions - of which Zinc is the first listed.

NCT06567717 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06567717 about?

NCT06567717 is a clinical study titled "Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis". The goal of this clinical trial is to learn if a clinical trial for idiopathic pulmonary fibrosis (IPF) can recruit and retain participants from their home to study whether a combination of zinc and nicotinamide riboside can treat iIPF. The main questions are: Can the investigators recruit particip...

What is the current status of trial NCT06567717?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-11-03. Estimated completion is 2027-01.

What conditions does trial NCT06567717 study?

This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.

What interventions are being tested in trial NCT06567717?

The interventions under investigation include: Zinc (DRUG), Placebos for zinc and nicotinamide riboside (OTHER), Nicotinamide riboside (DRUG).

Who is sponsoring clinical trial NCT06567717?

This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06567717 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Idiopathic Pulmonary Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Idiopathic Pulmonary Fibrosis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.